Search

Your search keyword '"Murase, Katsuhito"' showing total 2 results
Start Over Author "Murase, Katsuhito" Journal bioorganic medicinal chemistry
Sorry, I don't understand your search. ×
2 results on '"Murase, Katsuhito"'

1. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.

Author

Rikimaru K, Wakabayashi T, Abe H, Tawaraishi T, Imoto H, Yonemori J, Hirose H, Murase K, Matsuo T, Matsumoto M, Nomura C, Tsuge H, Arimura N, Kawakami K, Sakamoto J, Funami M, Mol CD, Snell GP, Bragstad KA, Sang BC, Dougan DR, Tanaka T, Katayama N, Horiguchi Y, and Momose Y

Subjects
Acylation, Animals, Binding Sites, Blood Glucose drug effects, CHO Cells, COS Cells, Chlorocebus aethiops, Cricetinae, Crystallography, X-Ray, Humans, Hypoglycemic Agents chemistry, Hypoglycemic Agents pharmacokinetics, Hypoglycemic Agents pharmacology, Male, Models, Molecular, Protein Binding drug effects, Pyridines administration & dosage, Pyridines pharmacokinetics, Pyridines pharmacology, Rats, Wistar, Structure-Activity Relationship, Drug Design, Peroxisome Proliferator-Activated Receptors agonists, Pyridines chemistry, Sulfonamides chemistry, Sulfonamides pharmacology
Abstract

In our search for a novel class of non-TZD, non-carboxylic acid peroxisome proliferator-activated receptor (PPAR) γ agonists, we explored alternative lipophilic templates to replace benzylpyrazole core of the previously reported agonist 1. Introduction of a pentylsulfonamide group into arylpropionic acids derived from previous in-house PPARγ ligands succeeded in the identification of 2-pyridyloxybenzene-acylsulfonamide 2 as a lead compound. Docking studies of compound 2 suggested that a substituent para to the central benzene ring should be incorporated to effectively fill the Y-shaped cavity of the PPARγ ligand-binding domain (LBD). This strategy led to significant improvement of PPARγ activity. Further optimization to balance in vitro activity and metabolic stability allowed the discovery of the potent, selective and orally efficacious PPARγ agonist 8f. Structure-activity relationship study as well as detailed analysis of the binding mode of 8f to the PPARγ-LBD revealed the essential structural features of this series of ligands., (Copyright © 2012 Elsevier Ltd. All rights reserved.)

Published
2012
Full Text
View/download PDF

2. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.

Author

Rikimaru K, Wakabayashi T, Abe H, Imoto H, Maekawa T, Ujikawa O, Murase K, Matsuo T, Matsumoto M, Nomura C, Tsuge H, Arimura N, Kawakami K, Sakamoto J, Funami M, Mol CD, Snell GP, Bragstad KA, Sang BC, Dougan DR, Tanaka T, Katayama N, Horiguchi Y, and Momose Y

Subjects
Animals, Binding Sites, Carboxylic Acids chemistry, Computer Simulation, Diabetes Mellitus, Experimental drug therapy, Disease Models, Animal, Humans, Hypoglycemic Agents pharmacokinetics, Hypoglycemic Agents therapeutic use, PPAR gamma metabolism, Protein Structure, Tertiary, Rats, Sulfonamides pharmacokinetics, Sulfonamides therapeutic use, Thiazolidinediones chemistry, Drug Design, Hypoglycemic Agents chemical synthesis, PPAR gamma agonists, Pyrazoles chemistry, Sulfonamides chemistry
Abstract

Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) γ agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPARγ ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based agonists. In this study, we used an acylsulfonamide group as the ring-opening analog of TZD as an isosteric replacement of carboxylic acid moiety of 2; further, preliminary modification of the terminal alkyl chain on the sulfonyl group gave the lead compound 3c. Subsequent optimization of the resulting compound gave the potent agonists 25c, 30b, and 30c with high metabolic stability and significant antidiabetic activity. Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d., (Copyright © 2011. Published by Elsevier Ltd.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results